Effects of erythromycin and roxithromycin on oxidation of testosterone and nifedipine catalyzed by CYP3A4 in human liver microsomes

Journal of Toxicological Sciences

Volumn 21, Issue 4, 1996, Pages 215-226

  Yamazaki, Hiroshi ^a   Urano, Tomoko ^b   Hiroki, Shigeru ^c   Shimada, Tsutomu ^a  

^a OSAKA PREFECTURAL INSTITUTE OF PUBLIC HEALTH   (Japan)

^b SANOFI   (France)

^c Roussel Morishita Co Ltd   (Japan)

Author keywords

CYP3A4; Drug interaction; Erythromycin; Macrolide antibiotic; P450; Roxithromycin

Indexed keywords

CYTOCHROME P450; ERYTHROMYCIN; KETOCONAZOLE; NIFEDIPINE; ROXITHROMYCIN; TROLEANDOMYCIN;

ARTICLE; BIOTRANSFORMATION; CATALYSIS; COMPLEX FORMATION; DRUG EFFECT; DRUG OXIDATION; HUMAN; HUMAN TISSUE; HYDROXYLATION; LIVER MICROSOME; TESTOSTERONE METABOLISM;

EID: 0029823132     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.21.4_215     Document Type: Article

References (52)

1. Birkett, D. J., Mackenzie, P. I., Veronese, M. E. and Miners, J. O (1993) : In vitro approaches can predict human drug metabolism. Pharamacol. Sci., 14, 292-294.
2. Chang, T., Gonzalez, F. J. and Waxman, D. J. (1994) : Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem. Biophys., 311, 437-442.
3. Delaforge, M., Sartori, E. and Mansuy, D. (1988) : In vivo and in vitro effects of a new macrolide antibiotic roxithromycin on rat liver cytochrome P-450 : comparison with troleandomycin and erythromycin. Chem Biol. Interact., 68, 179-188.
4. Echizen, H., Kawasaki, H., Chiba, K., Tani, M. and Ishizaki, T. (1993) : A potent inhibitory effect of erythromycin and other macrolide antibiotics on the mono-N-dealkylation metabolism of disopyramide with human liver microsomes. J. Pharmacol Exp. Ther., 264, 1425-1431.
5. Franklin, M. R. (1991) : Cytochrome P450 metabolite intermediate complexes from macrolide antibiotics and related compounds. Methods Enzymol., 206, 559-573.
6. Ged, C., Rouillon, J. M., Pichard, L., Combalbert, J., Bressot, N., Bories, P., Michel, H., Beaune, P. and Maurel, P. (1989) : The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br. J. Clin. Pharmacol., 28, 373-387.
7. George, J. and Farrell, G. C. (1991) : Role of human hepatic cytochromes P450 in drug metabolism and toxicity. Aust. Nz. J. Med., 21, 356-362.
8. Gibaldi, M. (1993) : Stereoselective and isozymeselective drug interactions. Chirality, 5, 407-413.
9. Gillam, E., Baba, T., Kim, B. R., Ohmori, S. and Guengerich, F. P. (1993) : Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. Arch. Biochem. Biophys., 305, 123-131.
10. Gillam, E. M. J., Guo, Z., Ueng, Y. -F., Yamazaki, H., Cock, I., Reilly, P. E. B., Hopper, W. D. and Guengerich, F. P. (1995) : Expression of cytochrome P450 3A5 in Escherichia coli : Effects of 5′ modification, purification, spectral characterization, reconstitution conditions, and catalytic activities. Arch. Biochem. Biophys., 317, 374-384.
11. Gonzalez, F. J. (1990) : Molecular genetics of the P-450 superfamily. Pharmacol. Ther., 45, 1-38.
12. Gonzalez, F. J. and Korzekwa, K. R. (1995) : Cytochromes P450 expression systems. Ann. Rev. Pharmacol. Toxicol., 35, 369-390.
13. Guengerich, F. P., Wang, P. and Davidson, N. K. (1982) : Estimation of isozymes of microsomal cytochrome P-450 in rats, rabbits, and humans using immunochemical staining coupled with sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Biochemistry. 21, 1698-1706.
14. Guengerich, F. P., Martin, M. V., Beaune, P. H., Kremers, P., Wolff, T. and Waxman, D. J. (1986) : Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem., 261, 5051-5060.
15. Guengerich, F. P. (1990) : Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene- Chem. Res. Toxicol., 3, 363-371.
16. Guengerich, F. P. (1994) : Analysis and characteriza- tion of enzymes. In Principles and Methods of Toxicology, 3rd Ed., (A. W. Hayes., ed.), pp. 1259-1313, Raven Press, New York.
17. Guengerich, F. P. and Shimada, T. (1991) : Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem. Res. Toxicol., 4, 391-407.
18. Halpert, J. R., Gengerich, F. P., Bend, J. R. and Correia, M. A. (1994) : Selective inhibitors of cytochromes P450. Toxicol. Appl. Pharmacol., 125, 163-175.
19. Honig, P. K., Woosley, R. L., Zamani, K., Conner, D. P. and Cantilena, Jr., L. R. (1992) : Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin. Pharmacol. Ther., 52, 231-238.
20. Honig, P. K., Wortham, D. C., Zamani, K., Conner, D. P., Mullin, J. C. and Cantilena, L. R. (1993) : Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. J. Amer. Med. Assoc., 269, 1513-1518.
21. Iwasaki, K., Matsuda, H., Nagase, K., Shiraga, T., Tokuma, Y. and Uchida, K. (1993) : Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes. Res. Commun. Chem. Path. Pharmacol., 82, 209-216.
22. Jurima-Romet, M., Crawford, K., Cyr, T. and Inaba, T. (1994) : Terfenadine metabolism in human liver in vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab. Dispos., 22, 849-857.
23. Kaminsky, L. S., Fasco, M. J. and Guengerich, F. P. (1981) : Production and application of antibodies to rat liver cytochrome P-450. Methods Enzymol., 74, 262-272.
24. Ketterer, T. A., Flockhart, D. A., Post, R. M., Denicoff, K., Pazzaglla, P. J., Marangell, L. B., George. M. S. and Callahan, A. M. (1995) : The emerging role of cytochrome P450 3A in psychopharmacology. J. Clin. Psychopharmacol., 15, 387-398.
25. Kivistö K. T., Neuvonen, P. J. and Klotz, U. (1994) : Inhibition of terfenadine metabolism. Clin. Pharmacokinet., 27, 1-5.
26. Kocarek, T. A., Schuetz, E. G., Strom, S. C., Fisher, R. A. and Guzelian, P. S. (1995) : Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes. Drug Metab. Dispos., 23, 415-421.
27. Larrey, D., Funck-Brentano, C., Breil, P., Vitaux, J., Theodore, C., Babany, G. and Pessayre, D. (1983a) : Effects of erythromycin on hepatic drug metabolizing enzymes in humans. Biochem. Pharmacol., 32, 1063-1068.
28. Larrey, D., Tinel, M. and Pessayre, D. (1983b): Formation of inactive cytochrome P-450 Fe(II)-metabolite complexes with several erythromycin derivatives but not with josamycin and midecamycin in rats. Biochem. Pharmacol., 32, 1487-1493.
29. Lindstrom, T. D., Haussen, B. R. and Wrighton, S. A. (1993) : Cytochrome P-450 complex formation by dirithromycin and other macrolides in rat and human livers. Antimicrob. Agents Chemother., 37, 265-269.
30. Lowry, O. H., Rosebrough, N. J., Farr, A. L. and Randall, R. J. (1951) : Protein measurement with the Folin phenol reagent. J. Biol. Chem., 193, 265-275.
31. Murray, M. and Reidy, G. F. (1990) : Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. Pharmacol. Rev., 42, 85-101.
32. Nelson, D. R., Kamataki, T., Waxman, D. J., Guengerich, F. P., Estabrook, R. W., Feyereisen, R., Gonzalez, F. J., Coon, M. J., Gunsalus, I. C., Gotoh, O., Okuda, K. and Nebert, D. W. (1993) : The P450 superfamily : update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol., 12, 1-51.
33. Ohmori, S., Ishii, I., Kuriya, S., Taniguchi, T., Rikihisa, T., Hirose, S., Kanakubo, Y. and Kitada, M. (1993) : Effects of clarithromycin and its mrtabolites on the mixed function oxidase system in hepatic microsomes of rats. Drug Metab. Dispos., 21, 358-363.
34. Omura, T. and Sato, R. (1964) : The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem., 239, 2370-2378.
35. Pessayre, D., Larrey, D., Vitaux, J., Breil, P., Belghiti, J. and Benhamou, J. -P. (1982) : Formation of an inactive cytochrome P-450 Fe(II)-metabolite complex after administration of troleandomycin in humans. Biochem. Pharmacol., 31, 1699-1704.
36. Ring, B. J., Binkley, S. N., Roskos, L. and Wrighton, S. A. (1995) : Effect of fluoxetine, norfluoxetine, sertraline and desmethyl sertraline on human CYP3A catalyzed 1-hydroxy midazolam formation in vitro. J. Pharmacol. Exp. Ther., 275. 1131-1135.
37. Schellens, J., Van, D. W. J., Brugman, M. and Breimer, D. D. (1993) : Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin, and antipyrine in humans as assessed by a cocktail study design. J. Pharmacol. Exp. Ther., 249, 638-645.
38. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y. and Guengerich, F. P. (1994) : Imerindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals : Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 270, 414-423.
39. Skett, P., Tyson, C., Guillouzo, A. and Maier, P. (1995) : Report on the international workshop on the use of human in vitro liver preparations to study drug metabolism in drug development. Biochem. Pharmacol., 50, 280-285.
40. Spatzenegger, M. and Jaeger, W. (1995) : Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metab. Rev., 27, 397-417.
41. Swinney, D. C. (1991) : Progesterone metabolism in hepatic microsomes. Effect of the cytochrome P-450 inhibitor, ketoconazole, and the NADPH 5a-reductase inhibitor, 4-MA, upon the metabolic profile in human, monkey, dog. and rat. Drug Metab. Dispos., 18, 859-865.
42. Taniguchi, H., Imai, Y., Iyanagi, T and Sato, R. (1979) : Interaction between NADPH-cytochrome P-450 reductase and cytochrome P-450 in the membrane of phosphatidylcholine vesicles. Biochim. Biophys. Acta, 550, 341-356.
43. Tinel, M., Descatoire, V., Larrey, D., Loeper, J., Labbe, G., Letteron, P. and Pessayre, D. (1989) : Effects of clarithromycin on cytochrome P-450. Comparison with other macrolides. J. Pharmacol. Exp. Ther., 250, 746-751.
44. Ueng, Y. -F., Shimada, T., Yamazaki, H. and Guengerich, F. P. (1995) : Oxidation of aflatoxin B1 by bacterial recombinant human cytochrome P450 enzymes. Chem. Res. Toxicol., 8, 218-225.
45. Watkins, P. B. (1994) : Noninvasive tests of CYP3A enzymes. Pharmacogenetics, 4, 171-184.
46. Wilkinson, G. R. (1987) : Clearance approaches in pharmacology. Pharmacol. Rev., 39, 1-47.
47. Wrighton, S. A. and Stevens, J. C. (1992) : The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol., 22, 1-21.
48. Wrighton, S. A., Ring, B. J. and Vandenbranden, M. (1995) : The use of in vitro metabolism techniques in the planning and interpretation of drug safety studies. Toxicol. Pathol., 23, 199-208.
49. Yamazaki, H., Inui, Y., Wrighton, S. A., Guengerich, F. P. and Shimada, T. (1995a) : Procarcinogen activation by cytochrome P450 3A4 and 3A5 expressed in Escherichia coli and by human liver microsomes. Carcinogenesis. 16, 2167-2170.
50. Yamazaki, H., Ueng, Y. -F., Shimada, T. and Guengerich, F. P. (1995b) : Roles of divalent metal ions in oxidations catalyzed by recombinant cytochrome P450 3A4 and replacement of NADPH-cytochrome P450 reductase with other flavoproteins, ferredoxin. and oxygen surrogates. Biochemistry, 34, 8380-8389.
51. 5 in the oxidation of testosterone and nifedipine by recornbinant cytochrome P450 3A4 and by human liver microsomes. Arch. Biochem. Biophys., 325, 174-182.
52. Yasukochi, Y. and Masters, B. (1976) : Some properties of a detergent-solubilized NADPH-cytochrome c (cytochrome P-450) reductase purified by biospecific affinity chromatography. J. Biol. Chem., 251, 5337-5344.